Wafer comprising steroid hormones
    2.
    发明申请
    Wafer comprising steroid hormones 有权
    晶体包含类固醇激素

    公开(公告)号:US20060222708A1

    公开(公告)日:2006-10-05

    申请号:US11391646

    申请日:2006-03-28

    IPC分类号: A61K9/22 A61K31/57

    CPC分类号: A61K31/56 A61K31/568

    摘要: The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in the mouth preferably in a period of less than 30 min, and the steroid hormone entering the bloodstream transmucosally from the administration system leads to a rapid rise in the concentration in the blood. It is thus possible to achieve a maximum concentration of this steroid hormone in the blood in a period of less than 60 min after administration.

    摘要翻译: 本发明涉及以类固醇激素经粘膜给药的薄膜形式的药物组合物。 公开了一种溶解在口中并以高生物利用度释放的类固醇激素的给药系统。 薄膜形式的给药系统优选在小于30分钟的时间内溶解于口腔内,并且通过管理系统经粘膜进入血液的类固醇激素导致血液中浓度的快速上升。 因此,可以在给药后小于60分钟的时间内实现血液中该类固醇激素的最大浓度。

    Multistage preparation for contraception based on natural estrogens
    4.
    发明申请
    Multistage preparation for contraception based on natural estrogens 审中-公开
    基于天然雌激素的避孕多步骤准备

    公开(公告)号:US20050032756A1

    公开(公告)日:2005-02-10

    申请号:US10891729

    申请日:2004-07-15

    IPC分类号: A61K31/57 A61K31/56

    CPC分类号: A61K31/57 A61K2300/00

    摘要: A multistage preparation for contraception based on a combination of natural estrogen and synthetic gestogen is described. The preferred preparation contains estradiol valerate as the natural estrogen and dienogest or drospirenone as the synthetic gestogen. In comparison to conventional multistage preparations the multistage preparation according to the invention has a higher contraceptive reliability over the entire cycle, improved cyclic bleeding behavior and minimizes or prevents side effects, such as breast tension, headaches, depressive moods and libido changes.

    摘要翻译: 描述了基于天然雌激素和合成gestogen的组合的用于避孕的多级制剂。 优选的制剂包含戊酸雌二醇作为天然雌激素和依诺孕酮或屈螺酮作为合成孕酮。 与常规多级制剂相比,根据本发明的多级制剂在整个循环中具有更高的避孕可靠性,改善的循环出血行为并且最小化或预防副作用,例如乳房张力,头痛,抑郁情绪和性欲改变。

    Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations
    5.
    发明授权
    Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations 失效
    含有高浓度类固醇的均质预制品,用于生产低剂量固体和半固体药物制剂

    公开(公告)号:US06290931B1

    公开(公告)日:2001-09-18

    申请号:US09319802

    申请日:1999-06-10

    IPC分类号: A61K912

    摘要: A homogeneous steroid-containing preformulation for production of solid and semi-solid pharmaceutical preparations containing a uniform constant dosage of at least one steroid in a range from 0.001 to 1 percent by weight is described. This steroid-containing preformulation contains of from 0.001 to 50 percent by weight of the at least one steroid. The homogeneous steroid-containing preformulation is made by a method including dissolving the at least one steroid in a solvent to form a dispersant; dispersing an adjuvant consisting of adjuvant particles in the dispersant in a mass ratio of the adjuvant to the at least one steroid of 1:1 to 1000:1 to form a suspension; and creating a spray-mist of the suspension so as to evaporate and remove the solvent from the suspension and thus to form a dried particulate which includes steroid-containing particles. The droplets in the spray mist have a droplet diameter greater than a mean diameter of the adjuvant particles. The maximum particle size of the dried particulate forming the steroid-containing preformulation is increased by less than 30 percent in comparison to an average particle size of the adjuvant particles.

    摘要翻译: 描述了用于生产固体和半固体药物制剂的均匀类固醇预制剂,其含有0.001至1重量%范围内的至少一种类固醇的均匀恒定剂量。 该含类固醇的预制剂含有0.001至50重量%的至少一种类固醇。 通过包括将至少一种类固醇溶解在溶剂中以形成分散剂的方法制备含均匀类固醇的预配制剂; 将助剂颗粒组成的佐剂以佐剂与至少一种类固醇的质量比为1:1至1000:1分散在分散剂中以形成悬浮液; 并产生悬浮液的喷雾,从而从悬浮液中蒸发除去溶剂,从而形成包含类固醇颗粒的干燥颗粒。 喷雾中的液滴的液滴直径大于辅助颗粒的平均直径。 与佐剂颗粒的平均粒径相比,形成含类固醇的预制剂的干燥颗粒的最大粒度增加小于30%。

    Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same
    6.
    发明授权
    Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same 失效
    含有睾酮/睾酮酯混合物的生物粘附片剂和用于产生具有相同的预定睾酮时间释放特性的方法

    公开(公告)号:US06977083B1

    公开(公告)日:2005-12-20

    申请号:US09806639

    申请日:1999-09-30

    IPC分类号: A61F13/00 A61K9/00

    CPC分类号: A61K9/006

    摘要: The method of making a bioadhesive tablet for controlling testosterone blood level, especially in elderly men suffering from partial androgen deficiency, includes spray-drying an alcoholic solution or suspension of testosterone and at least one testosterone ester, preferably in a ratio of 1:10 to 1:1.5, separately or together, with an organic polymer and optionally one or more auxiliary ingredient to form an active ingredient premix. Then various other auxiliary ingredients are mixed, as needed, with the active ingredient premix to form the bioadhesive tablet with an active ingredient layer and an adhesive layer. The active ingredient layer contains an effective amount of the active ingredient premix. The adhesive layer includes auxiliary ingredients including the bioadhesive polymer. The bioadhesive tablet may be buccally administered to provide a predetermined timed release profile of testosterone, advantageously varying according to a circadian rhythm.

    摘要翻译: 制备用于控制睾酮血液水平的生物粘附片剂的方法,特别是在患有部分雄激素缺乏症的老年男性中,包括将睾酮和至少一种睾酮酯的醇溶液或悬浮液喷雾干燥,优选1:10至 1:1.5,分别或一起与有机聚合物和任选的一种或多种辅助成分形成活性成分预混物。 然后根据需要将各种其它辅助成分与活性成分预混合物混合以形成具有活性成分层和粘合剂层的生物粘附片剂。 活性成分层含有有效量的活性成分预混物。 粘合层包括辅助成分,包括生物粘附聚合物。 生物粘附片剂可以经口给药以提供睾酮的预定定时释放曲线,其有利地根据昼夜节律改变。

    Injectable implant
    7.
    发明授权
    Injectable implant 失效
    可注射植入物

    公开(公告)号:US06303137B1

    公开(公告)日:2001-10-16

    申请号:US09341206

    申请日:1999-08-16

    IPC分类号: A61F202

    摘要: This invention relates to an in-situ implant that can be produced by placing a sterile, injectable, and water-insoluble complex from a biodegradable polymer and a biocompatible polyether with functional end-groups in the organism, and coagulating them under the influence of the body fluid. This coagulate may optionally contain at least one bioactive substance selected from the group of hormones, immunomodulators, immunosuppressants, antibiotics, cytostatics, diuretics, gastro-intestinal agents, analgesics, local anaesthetics and/or neuropharmacological agents.

    摘要翻译: 本发明涉及一种原位植入物,其可以通过将生物可降解聚合物和具有功能性端基的生物相容性聚醚与生物相容性聚合物置于无菌,可注射和水不溶性复合物的生物体中,并在其影响下凝结 体液。 该凝结物可以任选地含有至少一种选自激素,免疫调节剂,免疫抑制剂,抗生素,细胞抑制剂,利尿剂,胃肠药,止痛剂,局部麻醉剂和/或神经药物剂的生物活性物质。

    Combination compound for contraception based on natural estrogen
    8.
    发明授权
    Combination compound for contraception based on natural estrogen 失效
    基于天然雌激素的避孕组合化合物

    公开(公告)号:US6133251A

    公开(公告)日:2000-10-17

    申请号:US738314

    申请日:1996-10-25

    CPC分类号: A61K31/57 Y10S514/843

    摘要: The combination preparation for contraception includes a first stage of 2 to 4 first stage daily dosage portions, a second stage of two groups of second stage daily dosage portions, a third stage of 2 to 4 third stage daily dosage portions and an additional stage of 2 to 4 additional stage daily dosage portions. The first stage daily dosage portion is an effective amount of natural estrogen, the second stage daily dosage portion is an effective amount of a combination of natural estrogen and natural or synthetic gestogen, the third stage daily dosage portion is another effective amount of natural estrogen and an additional stage daily dosage portion consists of a placebo. The first group of the second stage consists of 3 to 5 daily dosage portions and the second group, 13 to 17 daily dosage portions. More of the gestogen is included in the effective amount in the second group of the second stage than in the first group. The effective amount of the natural estrogen is constant in both the first and third stages, but smaller in the third stage than in the first stage.

    摘要翻译: 用于避孕的组合制剂包括第一阶段的2至4个第一阶段每日剂量部分,第二阶段的两组第二阶段日剂量部分,第三阶段的2至4个第三阶段每日剂量部分和另外的阶段2 至4个额外的阶段日剂量部分。 第一阶段日剂量是天然雌激素的有效量,第二阶段日剂量是天然雌激素和天然或合成gestogen的组合的有效量,第三阶段日剂量是另一有效量的天然雌激素, 额外的阶段每日剂量部分由安慰剂组成。 第一组第一组由3〜5个日剂量组成,第二组为每日13〜17次。 第二组的第二组中有更多的gestogen包含在第一组中。 天然雌激素的有效量在第一和第三阶段都是恒定的,但在第三阶段中比在第一阶段更小。

    Combination preparation for contraception based on natural estrogens
    10.
    发明授权
    Combination preparation for contraception based on natural estrogens 失效
    基于天然雌激素的避孕组合制剂

    公开(公告)号:US06884793B2

    公开(公告)日:2005-04-26

    申请号:US09950915

    申请日:2001-09-12

    摘要: The combination preparation for contraception includes from 2 to 4 first stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient, from 16 to 22 second stage daily dosage portions each including an effective amount of a combination of at least one natural estrogen and at least one natural or synthetic gestogen as active ingredient; from 2 to 4 third stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient; and from 2 to 4 final stage daily dosage portions containing a pharmaceutically acceptable placebo. The estrogen may be estradiol, an estradiol compound that is metabolized to estradiol when taken into the body, a conjugated equine estrogen or a phytoestrogen. The natural or synthetic gestogen can be natural progesterone or a synthetic gestogens, such as medroxyprogesterone acetate.

    摘要翻译: 用于避孕的组合制剂包括2至4个第一阶段每日剂量部分,每个剂量部分包含有效量的至少一种天然雌激素作为唯一活性成分,16至22个第二阶段日剂量部分,每个包含有效量的组合 至少一种天然雌激素和至少一种天然或合成的Gestogen作为活性成分; 2至4个第三阶段每日剂量部分,每个包含有效量的至少一种天然雌激素作为唯一活性成分; 和含有药学上可接受的安慰剂的2至4个最终阶段每日剂量部分。 雌激素可以是雌二醇,当被摄入体内时被代谢为雌二醇的雌二醇化合物,共轭马雌激素或植物雌激素。 天然或合成的gestogen可以是天然孕酮或合成的gestogens,如醋酸甲羟孕酮。